New preliminary research suggests young women who exhibit obesity may have heart complications during and after pregnancy, including changes in heart structure and function—potentially leading to preeclampsia. Findings were presented at the American Heart Association’s Basic Cardiovascular Sciences Scientific Sessions.
Moderately elevated levels of LDL cholesterol and systolic blood pressure (SBP) that persist for a long time are just as dangerous as very elevated values over a shorter timeframe, according to a new study published in PLOS One.
Intensive blood pressure lowering helped reduce the risk of mild cognitive impairment (MCI), according to a substudy from the SPRINT trial presented last week at the Alzheimer’s Association International Conference in Chicago.
A hypertension management protocol from an integrated healthcare system was successfully adopted by a network of safety-net clinics, resulting in substantial improvements in blood pressure control for patients of all races.
The FDA on Friday, July 13, joined more than 20 other countries in recalling medications containing valsartan, an active ingredient used to treat hypertension and heart failure. Some of the medications with valsartan have been contaminated with N-nitrosodimethylamine (NDMA), a probable human carcinogen.
Adoption of the new 2017 American College of Cardiology/American Heart Association (ACC/AHA) hypertension guidelines would result in a “substantial” increase in the prevalence of hypertension in both the U.S. and China.
Valsartan, a common drug used to control hypertension and heart failure, is being recalled in 22 counties due to concerns its active pharmaceutical ingredient, N-Nitrosodimethylamine (NDMA), a known carcinogen, poses a cancer risk.
A program designed to help hypertensive patients with complex medication regimens understand the drugs they are prescribed not only failed to improve adherence, but it actually raised their blood pressure.
Patients with resistant hypertension and obstructive sleep apnea (OSA) experienced significant drops in blood pressure and improvements in OSA severity following renal denervation, according to a small randomized trial published June 25 in Hypertension.